Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Contributed by: Business Wire

Logo

Images

Almirall HQ in Barcelona (Photo: Business Wire)

Business Wire embedded0

Tags

Biotechnology

Pharmaceutical

Health

Other Health

Conference

More Like This

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Almirall photovoltaic installation in HQ Barcelona (Photo: Business Wire)

Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories

Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth